Accessible Machine Learning Approaches for Toxicology

[1]  Sean Ekins,et al.  Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. , 2010, Molecular bioSystems.

[2]  Franco Lombardo,et al.  Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. , 2004, Journal of medicinal chemistry.

[3]  H. van de Waterbeemd,et al.  Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.

[4]  S. Ekins.  Systems-ADME/Tox: resources and network approaches. , 2006, Journal of pharmacological and toxicological methods.

[5]  F. Lombardo,et al.  ElogPoct: a tool for lipophilicity determination in drug discovery. , 2000, Journal of medicinal chemistry.

[6]  Sean Ekins,et al.  Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. , 2005, Trends in pharmacological sciences.

[7]  Igor V Tetko,et al.  A renaissance of neural networks in drug discovery , 2016, Expert opinion on drug discovery.

[8]  Gisbert Schneider,et al.  Deep Learning in Drug Discovery , 2016, Molecular informatics.

[9]  Antony J. Williams,et al.  ChemSpider:: An Online Chemical Information Resource , 2010 .

[10]  Sean Ekins,et al.  Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. , 2012, Drug discovery today.

[11]  C. Steinbeck,et al.  Recent developments of the chemistry development kit (CDK) - an open-source java library for chemo- and bioinformatics. , 2006, Current pharmaceutical design.

[12]  Sean Ekins,et al.  Predicting Mouse Liver Microsomal Stability with “Pruned” Machine Learning Models and Public Data , 2015, Pharmaceutical Research.

[13]  O. Stegle,et al.  Deep learning for computational biology , 2016, Molecular systems biology.

[14]  Sean Ekins,et al.  A quality alert and call for improved curation of public chemistry databases. , 2011, Drug discovery today.

[15]  Sean Ekins,et al.  Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties , 2010, Drug Metabolism and Disposition.

[16]  Alexander Golbraikh,et al.  QSAR Modeling of the Blood–Brain Barrier Permeability for Diverse Organic Compounds , 2008, Pharmaceutical Research.

[17]  Barry A. Bunin,et al.  Chemical Space: Missing Pieces in Cheminformatics , 2010, Pharmaceutical Research.

[18]  Sean Ekins,et al.  Enhancing Hit Identification in Mycobacterium tuberculosis Drug Discovery Using Validated Dual-Event Bayesian Models , 2013, PloS one.

[19]  Sean Ekins,et al.  Identification and Validation of Novel Human Pregnane X Receptor Activators among Prescribed Drugs via Ligand-Based Virtual Screening , 2011, Drug Metabolism and Disposition.

[20]  Sean Ekins,et al.  Development of Computational Models for Enzymes, Transporters, Channels, and Receptors Relevant to ADME/Tox , 2004 .

[21]  Sarah R. Langdon,et al.  Predicting cytotoxicity from heterogeneous data sources with Bayesian learning , 2010, J. Cheminformatics.

[22]  David M. Reif,et al.  Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway , 2014, Scientific Reports.

[23]  Sean Ekins,et al.  Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  Björn Krüger,et al.  The holistic integration of virtual screening in drug discovery. , 2013, Drug discovery today.

[25]  W Patrick Walters,et al.  Prediction of 'drug-likeness'. , 2002, Advanced drug delivery reviews.

[26]  Joel S. Freundlich,et al.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. , 2011, Trends in Microbiology.

[27]  Carole A. Goble,et al.  Taverna: a tool for building and running workflows of services , 2006, Nucleic Acids Res..

[28]  Sean Ekins,et al.  Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development. , 2010, Lab on a chip.

[29]  S. Ekins,et al.  Progress in predicting human ADME parameters in silico. , 2000, Journal of pharmacological and toxicological methods.

[30]  Robert P. Sheridan,et al.  Comparison of Topological, Shape, and Docking Methods in Virtual Screening , 2007, J. Chem. Inf. Model..

[31]  Sean Ekins,et al.  Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. , 2010, Chemical research in toxicology.

[32]  Sean Ekins,et al.  A Predictive Ligand-Based Bayesian Model for Human Drug-Induced Liver Injury , 2010, Drug Metabolism and Disposition.

[33]  Sean Ekins,et al.  Challenges Predicting Ligand-Receptor Interactions of Promiscuous Proteins: The Nuclear Receptor PXR , 2009, PLoS Comput. Biol..

[34]  H. Mewes,et al.  Can we estimate the accuracy of ADME-Tox predictions? , 2006, Drug discovery today.

[35]  Anthony E. Klon,et al.  Improved Naïve Bayesian Modeling of Numerical Data for Absorption, Distribution, Metabolism and Excretion (ADME) Property Prediction , 2006, J. Chem. Inf. Model..

[36]  Sean Ekins,et al.  Making Transporter Models for Drug–Drug Interaction Prediction Mobile , 2015, Drug Metabolism and Disposition.

[37]  Alex M. Clark,et al.  New target prediction and visualization tools incorporating open source molecular fingerprints for TB Mobile 2.0 , 2014, Journal of Cheminformatics.

[38]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[39]  Robert P. Sheridan,et al.  Deep Neural Nets as a Method for Quantitative Structure-Activity Relationships , 2015, J. Chem. Inf. Model..

[40]  Sean Ekins,et al.  Progress in computational toxicology. , 2014, Journal of pharmacological and toxicological methods.

[41]  Sean Ekins,et al.  Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. , 2010, Molecular pharmaceutics.

[42]  Brian B. Masek,et al.  Sharing Chemical Information without Sharing Chemical Structure , 2008, J. Chem. Inf. Model..

[43]  Sean Ekins,et al.  Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). , 2013, Molecular pharmaceutics.

[44]  Sean Ekins,et al.  A collaborative database and computational models for tuberculosis drug discovery. , 2010, Molecular bioSystems.

[45]  Sean Ekins,et al.  A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis. , 2012, Molecular pharmaceutics.

[46]  S. Ekins,et al.  Present and future in vitro approaches for drug metabolism. , 2000, Journal of pharmacological and toxicological methods.

[47]  F. Lombardo,et al.  Computation of brain-blood partitioning of organic solutes via free energy calculations. , 1996, Journal of medicinal chemistry.

[48]  Alex M. Clark,et al.  Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets , 2015, J. Chem. Inf. Model..

[49]  Sean Ekins,et al.  Comprehensive computational assessment of ADME properties using mapping techniques. , 2005, Current drug discovery technologies.

[50]  Andy Liaw,et al.  Extreme Gradient Boosting as a Method for Quantitative Structure-Activity Relationships , 2016, J. Chem. Inf. Model..

[51]  Barry A. Bunin,et al.  Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery. , 2013, Chemistry & biology.

[52]  John B. O. Mitchell.  Machine learning methods in chemoinformatics , 2014, Wiley interdisciplinary reviews. Computational molecular science.

[53]  Dave Winkler,et al.  Bayesian Regularization of Neural Networks , 2009, Artificial Neural Networks.

[54]  Sean Ekins,et al.  Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis. , 2014, Tuberculosis.

[55]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[56]  Sean Ekins,et al.  Evolving molecules using multi-objective optimization: applying to ADME/Tox. , 2010, Drug discovery today.

[57]  Hao Zhu,et al.  Big Data in Chemical Toxicity Research: The Use of High-Throughput Screening Assays To Identify Potential Toxicants , 2014, Chemical research in toxicology.

[58]  Sean Ekins,et al.  Targeting drug transporters - combining in silico and in vitro approaches to predict in vivo. , 2010, Methods in molecular biology.

[59]  Antony J. Williams,et al.  Bigger data, collaborative tools and the future of predictive drug discovery , 2014, Journal of Computer-Aided Molecular Design.

[60]  Jing-Tao Wu,et al.  Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. , 2005, Current topics in medicinal chemistry.

[61]  Tudor I. Oprea,et al.  Integrating virtual screening in lead discovery. , 2004, Current opinion in chemical biology.

[62]  T. Nikolskaya,et al.  A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT , 2006, Drug Metabolism and Disposition.

[63]  Sean Ekins,et al.  Troubleshooting computational methods in drug discovery. , 2010, Journal of pharmacological and toxicological methods.

[64]  Geoffrey E. Hinton,et al.  Deep Learning , 2015, Nature.

[65]  B Testa,et al.  In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.

[66]  Olivier Sperandio,et al.  FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects , 2008, BMC Bioinformatics.

[67]  Sean Ekins,et al.  Are Bigger Data Sets Better for Machine Learning? Fusing Single-Point and Dual-Event Dose Response Data for Mycobacterium tuberculosis , 2014, J. Chem. Inf. Model..

[68]  T. Nikolskaya,et al.  Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[69]  Sean Ekins,et al.  Molecular Determinants of Ligand Selectivity for the Human Multidrug and Toxin Extruder Proteins MATE1 and MATE2-K , 2012, Journal of Pharmacology and Experimental Therapeutics.

[70]  S. Ekins,et al.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.

[71]  Sean Ekins,et al.  Pharmacophores for Human ADME/Tox‐Related Proteins , 2006 .

[72]  Sean Ekins,et al.  Computational prediction of human drug metabolism , 2005, Expert opinion on drug metabolism & toxicology.

[73]  S. Ekins,et al.  Application of in silico approaches to predicting drug--drug interactions. , 2001, Journal of pharmacological and toxicological methods.

[74]  William J. Welsh,et al.  New Predictive Models for Blood–Brain Barrier Permeability of Drug-like Molecules , 2008, Pharmaceutical Research.

[75]  Franco Lombardo,et al.  A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. , 2006, Journal of medicinal chemistry.

[76]  Julie Clark,et al.  Discovery of Novel Antimalarial Compounds Enabled by QSAR-Based Virtual Screening , 2013, J. Chem. Inf. Model..

[77]  Alex M. Clark,et al.  Open Source Bayesian Models. 3. Composite Models for Prediction of Binned Responses , 2016, J. Chem. Inf. Model..

[78]  C Helma,et al.  Validation of counter propagation neural network models for predictive toxicology according to the OECD principles: a case study , 2006, SAR and QSAR in environmental research.

[79]  Olivier Sperandio,et al.  Free resources to assist structure-based virtual ligand screening experiments. , 2007, Current protein & peptide science.

[80]  Franco Lombardo,et al.  Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. , 2002, Journal of medicinal chemistry.

[81]  Gábor Csányi,et al.  Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties , 2007, J. Chem. Inf. Model..

[82]  Sean Ekins,et al.  Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. , 2009, Molecular pharmaceutics.

[83]  Ruili Huang,et al.  Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. , 2011, Toxicology and applied pharmacology.

[84]  Lynn Rasmussen,et al.  Antituberculosis activity of the molecular libraries screening center network library. , 2009, Tuberculosis.

[85]  Lynn Rasmussen,et al.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. , 2009, Tuberculosis.

[86]  Alex Zhavoronkov,et al.  Applications of Deep Learning in Biomedicine. , 2016, Molecular pharmaceutics.

[87]  Egon L. Willighagen,et al.  CDK-Taverna: an open workflow environment for cheminformatics , 2010, BMC Bioinformatics.

[88]  Alex M. Clark,et al.  Open Source Bayesian Models. 2. Mining a "Big Dataset" To Create and Validate Models with ChEMBL , 2015, J. Chem. Inf. Model..

[89]  Sean Ekins,et al.  Novel Inhibitors of Human Organic Cation/Carnitine Transporter (hOCTN2) via Computational Modeling and In Vitro Testing , 2009, Pharmaceutical Research.